[TITLE]
[TEASER]
Related News
-
Press Releases
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained ...
The company announced today new two-year follow up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with TGCT.
2026/10/26